Silence Therapeutics (NASDAQ:SLN) Price Target Cut to $25.00 by Analysts at BMO Capital Markets

Silence Therapeutics (NASDAQ:SLN) had its price objective cut by stock analysts at BMO Capital Markets from $67.00 to $25.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price would suggest a potential upside of 447.05% from the company’s current price.

Other equities analysts have also issued research reports about the company. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th. The Goldman Sachs Group lowered their target price on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, January 29th. Finally, William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Silence Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Silence Therapeutics Trading Up 5.8 %

Silence Therapeutics stock traded up $0.25 during midday trading on Tuesday, hitting $4.57. 65,035 shares of the stock were exchanged, compared to its average volume of 315,461. The stock’s 50-day simple moving average is $5.58 and its 200 day simple moving average is $11.65. Silence Therapeutics has a fifty-two week low of $4.06 and a fifty-two week high of $27.72. The stock has a market capitalization of $136.78 million, a price-to-earnings ratio of -2.91 and a beta of 1.05.

Institutional Investors Weigh In On Silence Therapeutics

Several large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics during the fourth quarter worth approximately $26,000. GAMMA Investing LLC grew its holdings in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after acquiring an additional 5,233 shares in the last quarter. Barclays PLC increased its position in shares of Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after purchasing an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at $69,000. Finally, Virtus ETF Advisers LLC increased its holdings in Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after buying an additional 6,098 shares during the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.